• Skip to Content
• Skip to Navigation

Therapeutic Programs

Viamet develops traditional small molecule compounds that exploit validated metalloenzyme targets in the fields of infectious disease and oncology.  All of Viamet's therapeutic programs target indications with blockbuster potential and where current therapies have significant clinical deficiencies that can be addressed by the Company's proprietary Metallophile™ Technology.